Skip to main content
AORT
NYSE Industrial Applications And Services

Artivion Details Strong 2025 Performance, Above-Target Executive Payouts in Proxy Filing

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Medical Device Stocks · Healthcare
Sentiment info
Positive
Importance info
7
Price
$34.16
Mkt Cap
$1.636B
52W Low
$21.97
52W High
$48.25
52W Position info
55% above low
Off High info
29% below high
Rel. Volume info
2.0× avg
Market data snapshot near publication time

AORT sits 55% above its 52-week low of $21.97 on elevated volume (2.0× avg).

Summary

Artivion, Inc. filed its definitive proxy statement for its May 12, 2026, annual meeting, revealing strong 2025 financial performance with 13.2% constant currency revenue growth and 28.6% adjusted EBITDA growth, leading to above-target executive incentive payouts and high shareholder approval for executive compensation.


Key Events · Corporate Governance and Compliance · AORT

  • Annual Meeting Scheduled

    The company will hold its annual meeting on May 12, 2026, to elect nine director nominees, conduct a non-binding advisory vote on executive compensation, and ratify Ernst & Young LLP as the independent registered public accounting firm for fiscal year 2026.

  • Strong 2025 Financial Performance

    Artivion achieved 13.2% constant currency revenue growth and 28.6% adjusted EBITDA growth in 2025, exceeding the predetermined targets for its incentive plans.

  • Above-Target Executive Incentive Payouts

    Due to the strong 2025 performance, executive officers received 118.7% of target payouts for both cash bonuses and performance stock units.

  • Significant CEO Compensation Tied to Performance

    The CEO's "Compensation Actually Paid" for 2025 totaled $17.4 million, reflecting the company's strong performance and the alignment of executive incentives with value creation.


Analysis · AORT · Industrial Applications And Services

This definitive proxy statement outlines the agenda for Artivion's upcoming annual meeting, highlighting key corporate governance matters. The most significant takeaway is the company's robust financial performance in 2025, with constant currency revenue growth of 13.2% and adjusted EBITDA growth of 28.6%, both exceeding targets. This strong operational execution directly translated into above-target incentive payouts for executive officers, including a substantial "Compensation Actually Paid" for the CEO. The high shareholder approval for executive compensation in the prior year suggests investor confidence in the pay-for-performance model. Investors should view the successful achievement of financial targets and the resulting executive incentives as a positive indicator of management's ability to drive growth and create value.

At the time of this filing, AORT was trading at $34.16 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $1.6B. The 52-week trading range was $21.97 to $48.25. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

AORT - Latest Insights

AORT
Jun 29, 2026, 7:00 AM EDT
Source: PR Newswire
Importance Score:
9
Price at Filing: $23.78
Real-time Price: $25.00 info
Change: +$1.22 (+5%) info
Market Cap: $1.227B info
AORT
May 18, 2026, 7:06 AM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $23.54
Real-time Price: $25.00 info
Change: +$1.46 (+6%) info
Market Cap: $1.227B info
AORT
May 08, 2026, 10:56 AM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $25.55
Real-time Price: $25.00 info
Change: -$0.550 (-2%) info
Market Cap: $1.227B info
AORT
May 07, 2026, 6:01 PM EDT
Source: Dow Jones Newswires
Importance Score:
9
Price at Filing: $27.98
Real-time Price: $25.00 info
Change: -$2.98 (-11%) info
Market Cap: $1.227B info
AORT
May 07, 2026, 4:43 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $24.40
Real-time Price: $25.00 info
Change: +$0.600 (+2%) info
Market Cap: $1.227B info